Feeds shared today: May 15, 2008
1 shares
More Americans snipping landlines in favor of cell phones
via Stories dugg by cgsheldon by (author unknown) on May 14, 2008
Mobile phones are steadily becoming the only phone in American households, according to a new study. The trend, however, signifies both positive and negative changes on the horizon.
Shared by: cgsheldon,
[ Back to top]
1 shares
EDITORIAL: Multiple Biomarker Panels for Cardiovascular Risk Assessment
via New England Journal of Medicine by de Lemos, J. A., Lloyd-Jones, D. M. on May 14, 2008
Guidelines for the assessment of cardiovascular risk remain focused squarely on established risk factors.1 Although it is known that tools based on these risk factors, such as the Framingham Risk ...
Shared by: Martin,
[ Back to top]
1 shares
EDITORIAL: Initial Treatment for HIV Infection -- An Embarrassment of Riches
via New England Journal of Medicine by Hirschel, B., Calmy, A. on May 14, 2008
Drugs that are used to treat patients with human immunodeficiency virus (HIV) infection are classified according to their target. The first ones to be developed were nucleoside reverse-transcriptase inhibitors (NRTIs), ...
Shared by: Martin,
[ Back to top]
1 shares
ORIGINAL ARTICLE: Efficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage
via New England Journal of Medicine by Mayer, S. A., Brun, N. C., Begtrup, K., Broderick, J., Davis, S., Diringer, M. N., Skolnick, B. E., Steiner, T., the FAST Trial Investigators on May 14, 2008
In a previous phase 2 placebo-controlled trial, recombinant activated factor VII (rFVIIa) reduced growth of the hematoma and improved survival and functional outcome in patients with intracerebral hemorrhage. Those findings were not reproduced in this phase 3 trial, in which rFVIIa reduced hematoma growth but did not improve clinical outcomes.
Shared by: Martin,
[ Back to top]
1 shares
ORIGINAL ARTICLE: Cardiac Troponin and Outcome in Acute Heart Failure
via New England Journal of Medicine by Peacock, W. F., De Marco, T., Fonarow, G. C., Diercks, D., Wynne, J., Apple, F. S., Wu, A. H.B., the ADHERE Investigators on May 14, 2008
In this large, retrospective registry study, patients hospitalized with acute decompensated heart failure who had elevated cardiac troponin levels had higher mortality rates than those who were negative for troponin, even after correction for other predictive variables. Measurement of cardiac troponin, which may reflect myocyte injury, is useful for risk stratification of such patients.
Shared by: Martin,
[ Back to top]
1 shares
ORIGINAL ARTICLE: Use of Multiple Biomarkers to Improve the Prediction of Death from Cardiovascular Causes
via New England Journal of Medicine by Zethelius, B., Berglund, L., Sundstrom, J., Ingelsson, E., Basu, S., Larsson, A., Venge, P., Arnlov, J. on May 14, 2008
To predict the risk of death from cardiovascular causes in a community-based cohort of elderly men, the authors used a combination of biomarkers (troponin I, N-terminal pro-brain natriuretic peptide, cystatin C, and C-reactive protein). The addition of these markers to a model with traditional cardiovascular risk factors significantly improved risk stratification as compared with a model that...
Shared by: Martin,
[ Back to top]
1 shares
EARLY RELEASE: The Aprotinin Story -- Is BART the Final Chapter?
via New England Journal of Medicine by Ray, W. A., Stein, C. M. on May 14, 2008
(No abstract is available for this citation)
Shared by: Martin,
[ Back to top]
1 shares
Entwicklungskosten-Mantra
via Stationäre Aufnahme by strappato on May 15, 2008
Die Pharmaindustrie stöhnt gerne über die Entwicklungskosten von neuen Medikamenten und rechtfertigt damit hohe Preise. Nur: genaue Summen sind unbekannt. Regelmässig wird das Mantra der 1 Milliarde Dollar für die Erforschung und Entwicklung eines neuen Medikamentes, oder auch in Deutschland gerne 800 Millionen Dollar, runtergebetet.Marcia Angell, früher Herausgeberin des NEJM, hat in ihrem...
Shared by: Martin,
[ Back to top]
2 shares
Atom-powered Mini-tablet Confirmed By Intel Germany CEO?
via The Unofficial Apple Weblog (TUAW) by Steven Sande on May 15, 2008
Filed under: Analysis / Opinion, Hardware, Rumors, iPhoneWas it a slip of the tongue? ZDNet.de reports that Intel Germany CEO Hannes Schwaderer, speaking at an Intel 40th anniversary event at Munich's BMW World, confirmed that there is an iPhone that will be using Intel's new Atom processor. The new device is "slightly larger" than the current iPhone, raising speculation that this new...
Shared by: Mehrdad, Ram H. Viswanathan,
[ Back to top]
1 shares
Quality standards in Q&A
via Liberating the literature by Jon Brassey on May 15, 2008
At the start of the week I had the pleasure of presenting at the 2008 Clinical Librarian Study Day. I was tasked with talking about quality standards in Q&A. This was a tough subject to do justice. I've worked hard for ten years on Q&A yet had never really thought about 'standards'. So it took a while to distill my thinking into reasonable standards.I came up with two types of...
Shared by: Martin,
[ Back to top]